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Adequate levels of vitamins and minerals are essential for optimal neural functioning. A high proportion of individuals, including children, suffer
from deficiencies in one or more vitamins or minerals. This study investigated whether daily supplementation with vitamins/minerals could modu-
late cognitive performance and mood in healthy children. In this randomised, double-blind, placebo-controlled, parallel groups investigation,
eighty-one healthy children aged from 8 to 14 years underwent laboratory assessments of their cognitive performance and mood pre-dose and
at 1 and 3 h post-dose on the first and last days of 12 weeks’ supplementation with a commercially available vitamins/mineral product (Pharmaton
Kiddie). Interim assessments were also completed at home after 4 and 8 weeks at 3 h post-dose. Each assessment comprised completion of a
cognitive battery, delivered over the Internet, which included tasks assessing mood and the speed and accuracy of attention and aspects of
memory (secondary, semantic and spatial working memory). The vitamin/mineral group performed more accurately on two attention tasks:
‘Arrows’ choice reaction time task at 4 and 8 weeks; ‘Arrow Flankers’ choice reaction time task at 4, 8 and 12 weeks. A single task outcome
(Picture Recognition errors) evinced significant decrements at 12 weeks. Mood was not modulated in any interpretable manner. Whilst it is
possible that the significant improvements following treatment were due to non-significant numerical differences in performance at baseline,
these results would seem to suggest that vitamin/mineral supplementation has the potential to improve brain function in healthy children.
This proposition requires further investigation.
Vitamins: Minerals: Cognitive performance: Attention: Children: Internet
Adequate levels of vitamins and minerals are essential for the
optimal performance of a host of physiological processes that
have both direct and indirect effects on brain function, includ-
ing neurotransmitter synthesis, receptor binding, membrane
ion pump function, energy metabolism and cerebral blood
flow(1,2). It is therefore unsurprising that a relationship has
been shown to exist, in cross-sectional and prospective studies,
between dietary consumption of vitamins and cognitive
performance. Much of this research has focused on elderly
populations, where positive relationships exist between
cognitive performance and either dietary intake, or endogen-
ous levels, of B vitamins(3–5) and vitamins C and E(6–8). Pre-
vious intake of these vitamins has also been shown to be
associated with a reduced risk of dementia(9).
The efficacy of direct supplementation with vitamins/min-
erals in terms of cognitive performance has received compara-
tively little attention. Evidence from the few studies in healthy
adults that have included an assessment of elements of cogni-
tive performance is somewhat equivocal(1) and this pattern is
sustained in elderly cohorts(1,10–13). However, it is notable
that where cognitive measures have been included in adult
and elderly studies they have tended to be secondary to
other primary outcomes of the respective studies, rather than
forming the focus of the investigation.
In the case of children, studies of supplementation with
multi-vitamins/minerals have generally assessed measures of
intelligence (or intelligence quotient) rather than cognitive
performance per se. The balance of evidence here seems to
suggest a propensity for improvement(1). For instance, Ben-
ton’s(14) review of the results of studies conducted in the pre-
vious decade notes that improved performance was seen in ten
out of thirteen studies following supplementation, but with this
restricted to non-verbal tests of intelligence. However, a recent
article(15) from the Nutrition Enhancement for Mental Optim-
ization study group concluded that fortification with multiple
micronutrients can result in improvements in verbal learning
and memory in well-nourished school-aged children.
Given that research suggests that a large proportion of the
population are failing to consume adequate levels of specific
vitamins in their normal diet(16–18) and that this situation is
being exacerbated in many societies by a significant negative
relationship between the consumption of ‘fast food’ and
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vitamins(19), it seems timely to revisit the possibility that
direct supplementation of children’s diets with a multi-vita-
min/mineral product will have a beneficial effect on cognitive
performance and/or mood.
The current randomised, double-blind, placebo-controlled,
parallel groups study therefore assessed the effects of a multi-
vitamin/mineral supplement on cognitive performance and
mood in a laboratory setting following 12 weeks’ supplemen-
tation. In this case, the product under investigation was a
widely available commercial supplement for children (Pharma-
ton Kiddie), which has not previously been subjected to any
similar investigation. The study utilised a purpose-programmed,
Internet-delivered cognitive and mood assessment battery. The
use of this novel assessment technique allowed further interim
assessments to be undertaken in the participants’ homes under
parental supervision after 4 and 8 weeks of supplementation.
There is also sparse but growing evidence that B, C and E vita-
mins are capable of positively influencing specific physiological
processes which our group has previously argued may be rel-
evant to cognition enhancement in the hours following single
administration(20,21). A secondary goal of the present study
was therefore to determine whether micronutrient adminis-
tration might have acute cognitive effects.
Methods and materials
Participants
A total of eighty-one male and female children aged 8 to 14
years took part in the study. They were recruited via posters
and emails to university staff and students, from direct con-
tact with schools in the surrounding area and further publi-
city via a newspaper article. All participants were reported
to be healthy and free from any food allergy or the use of
prescription, illicit, herbal or recreational drugs including
alcohol and tobacco. Exclusion criteria also included the
use of dietary supplements within the last 3 months and
diagnosis with any significant medical condition. Exclusion/
inclusion criteria were confirmed by questionnaire and inter-
view. Prior to taking part in the study all participants and
their parents provided written informed consent. The study
was approved by the Northumbria University School of
Psychology and Sport Science Ethics Committee and was
carried out in accordance with the Declaration of Helsinki.
Following a blind review of the data, three participants were
excluded on the basis that their data suggested that they had
failed to perform the tasks correctly according to pre-determined
criteria (i.e. performance across tasks that was at chance or con-
sistent with use of a single button, plus large variations in reac-
tion times suggesting inattention to the stimuli) on at least one
occasion. Three sets of data from the day 1 post-dose assess-
ments were also not captured due to a technical error. A further
ten participants failed to complete one or both of the two home
Internet assessments on the correct day/time. The blind data
review also suggested that in a small number of instances indi-
viduals had mis-performed single tasks. Scores from these
instances were excluded from the analysis.
Final datasets for analysis
In total, there were therefore seventy-five (placebo thirty-nine,
verum thirty-six) complete datasets ‘included’ in the ‘acute’
analysis, sixty-eight datasets (placebo thirty-five, verum
thirty-three) included in the ‘interim’ home Internet assess-
ment and seventy-eight datasets (placebo forty, verum thirty-
eight) included in the ‘chronic’ (full 12-week) analysis.
Where the analysis for a single task represents data from
less than these cohorts the number of participants contributing
is shown in the respective table.
Demographic data from the seventy-eight children whose
data was entered into the statistical analyses are presented
in Table 1.
Treatments
Throughout the study period participants were asked to take
two chewable tablets daily in the morning with breakfast.
The treatments (placebo and vitamins/minerals) were provided
by the manufacturer pre-coded according to a computer-gener-
ated randomisation list. All staff members at the investiga-
tional team remained unaware of the individuals’ treatments
until the completion of the blind data review.
During the laboratory visit days (days 1 and 85) the partici-
pants consumed their tablets at approximately 08.45 hours at
the investigational site with their standard breakfast. On
interim ‘home’ testing days (days 29 and 57), the participants
were asked to take their study medication at their own home
with their breakfast and to undertake the ‘Internet testing
battery’ 3 h post-dose.
Participants were asked to take their day’s tablets with their
breakfast on every other day throughout the study period. The
participant’s parents were provided with a diary comprising a
daily tick-box to initial as a means of confirming treatment
consumption for the day.
Depending on which group the participant was randomly
allocated to, the two chewable tablets comprised either Phar-
maton Kiddiw multi-vitamins/minerals (see Table 2 for details
of composition) or an inert placebo matching the verum
tablets in all other respects.
Diary and Internet data suggested that all of the participants
had ‘good’ (.80%) compliance with regard to the consump-
tion of daily treatments.
Cognitive and mood measures
Internet testing battery. The Internet battery comprised a
selection of cognitive tasks programmed in Java language.
Table 1. Demographic data from the seventy-eight participants who
contributed to the statistical analysis*
(Mean values and standard deviations)
Vitamins/minerals Placebo
Mean SD Mean SD
Male (n) 19 16
Female (n) 21 22
Age (years) 10·84 2·57 11·26 2·02
Height (m) 1·46 0·13 1·50 0·13
Weight (kg) 41·07 12·54 43·83 12·42
BMI (kg/m2) 18·93 4·57 19·28 3·61
There were no significant differences between treatment groups on these
parameters.
* For details of subjects and procedures, see Methods and materials.
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Timing of the test battery and reaction times were made
independently of the computer’s internal timing, guaranteeing
consistent presentation of stimuli and accurate timing of
responses. The presentation of parallel versions of stimuli
for each individual task was counterbalanced across the
assessments.
The battery included the following cognitive performance
elements (cognitive domain in brackets where appropriate)
and visual analogue mood items:
Word presentation: Fifteen words appropriate for the age
range of the participants drawn from the Economic and
Social Research Council’s ‘Children’s Printed Word Data-
base’ and matched for familiarity, concreteness and frequency
were presented at the commencement of the battery. Stimulus
duration was 1 s, as was the inter-stimulus duration.
Picture presentation: Twelve age-appropriate line drawings
of items (from Snodgrass & Vanderwart(22)) were presented
at the commencement of the battery. Stimulus duration was
1 s, with a 2 s inter-stimulus duration.
Arrow reaction time test (choice reaction): An arrow
appeared on the screen pointing to the left or right. Partici-
pants responded with a left or right arrow key press corre-
sponding to the direction of the arrow. Each of the eighty
stimuli remained on screen until the key press was registered.
There was a randomly varying inter-stimulus interval of
between 1 and 3 s. Outcomes were accuracy (i.e. % incorrect)
and reaction time (ms).
Arrow Flankers test (choice reaction): Five symbols
appeared on screen, with the centre symbol always being
an arrow pointing to the left or right. The task was to
press the right or left arrow key corresponding to the direc-
tion of the central arrow. The flanking pairs of symbols
could be squares, crosses, congruent arrows (pointing in
the same direction) or incongruent arrows (pointing in the
opposite direction). Each of the eighty stimuli remained
on screen until the key press was registered. There was a
randomly varying inter-stimulus interval of between 1 and
3 s. Outcomes were accuracy (i.e. % incorrect) and reaction
time (ms).
Paired associate learning (spatial working memory): Two
shape symbols (e.g. square, circle, triangle, etc) were dis-
played on the screen side by side for 3 s. Each of the two
symbols was then repeatedly presented alone in random
order in the centre of the screen for a total of ten rep-
etitions. The participant had to indicate if the symbol was
originally seen on the left or right with a corresponding
key press. A second pair of symbols was then presented
and the four symbols that were contained in the two pairs
were repeatedly presented (ten repetitions), with the partici-
pant once again indicating whether each symbol was origi-
nally presented on the left or right. This was repeated a
further two times until responses were being made to one
of eight symbols. Outcomes included the number of errors
and reaction times (ms).
Sentence verification (semantic memory retrieval): Fifty
short sentences appeared on screen that were either true
(e.g. ‘Bicycles have wheels’) or false (e.g. ‘Tomatoes have
wings’). Participants responded ‘true’ or ‘false’ via a key
press as quickly as possible. Outcomes included accuracy
(% errors) and reaction times (ms).
Delayed word recognition (secondary memory): Word rec-
ognition was tested by the re-presentation of the fifteen
words presented towards the beginning of the battery plus fif-
teen distractor words presented in random order. Participants
responded either ‘yes’ or ‘no’ by key press to indicate whether
the word had previously been presented. Outcomes included
accuracy (% errors) and reaction times (ms).
Delayed picture recognition (secondary memory): Picture
recognition was tested by the re-presentation of the twelve
drawings presented at the commencement of the battery plus
twelve distractor drawings presented in random order. Partici-
pants responded either ‘yes’ or ‘no’ by key press to indicate
whether the picture had previously been presented. Outcomes
included accuracy (% errors) and reaction times (ms).
Mood and fatigue visual analogue scales (mood): After
completion of the cognitive tasks, participants were then
asked to complete a computer-adapted version of the self-
report visual analogue scales (‘relaxed’, ‘alert’, ‘jittery’,
‘tired’, ‘tense’, ‘headache’, ‘overall mood’) that have been
used in previous research assessing dietary manipula-
tions(23,24). The scale was completed by using the computer
mouse to place a cross on a line that represented a continuum
between ‘not at all’ and ‘extremely’ for each of the seven
mood items and a further three; ‘mental fatigue’ (‘not at all’
to ‘extremely’) and the bi-polar items ‘Do you normally
feel’ ‘happy/sad?’ and ‘stressed/calm?’.
Chalder fatigue scale. The Chalder Fatigue Scale(25) com-
prises eleven items, each of which can be scored out of four.
These scores then aggregate into scores for physical and
mental symptoms. In this instance, the scale was administered
by the researcher in a verbal format, with the participant
required to answer each of the eleven questions on a four-
point scale (‘better than usual’; ‘no more than usual’; ‘worse
than usual’; ‘much worse than usual’).
Table 2. Constituents of the multi-vitamin/mineral supplement (Pharma-
ton Kiddiw)*
Active ingredients Dosage per tablet
L-Lysine monohydrochloride 50·00 mg
b-Carotene 0·514 mg
Vitamin A Vitamin A: 715 IU
Thiamine nitrate Vitamin B1 nitrate: 0·500 mg
Riboflavin Vitamin B2: 0·550 mg
Pyridoxine hydrochloride Vitamin B6 hydrochloride:
0·550 mg
Cyanocobalamin Vitamin B12: 0·600mg
Ascorbic acid Vitamin C: 22·00 mg
Vitamin D3 Vitamin D3: 3·75mg ¼ 150 IU
Vitamin E acetate
(d,L-a-tocopheryl acetate)
d,L-a-tocopheryl acetate:
5·215 mg ¼ 5·22 IU
d,L-a-tocopheryl
acetate ¼ 3·50 mg vitamin E
Folic acid 50mg
Biotin 15·00mg
Vitamin PP (nicotinamide) 6·00 mg
Copper(II)carbonate Cu: 0·3 mg
Calcium phosphate
(dibasic anhydrous)
Ca: 65·0 mg
Ferrous(II)fumarate Fe: 2·50 mg
Zinc oxide Zn: 2·50 mg
Magnesium oxide, heavy Mg: 12·5 mg
* For details of subjects and procedures, see Methods and materials.
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Procedure
Participants attended the laboratory on three separate
occasions at the weekend (practice day, day 1 and day 85).
Testing took place in a suite of testing facilities with partici-
pants visually isolated from each other.
The practice day comprised of obtaining informed consent,
training on the cognitive and mood measures and question-
naire measures, health screening, collection of demographic
and nutritional data and random allocation to treatment.
Participants also completed the Chalder Fatigue Scale at the
end of the visit.
Following the practice day, participants attended the labora-
tory at 08.00 hours on the first (day 1) and last (day 85) days
of the 12-week treatment regimen. On day 1, the participants
received three bottles of chewable tablets. On arrival on day 1
and day 85, participants completed a baseline assessment of
the Internet testing battery (see earlier). They then consumed
one of a number of standard breakfasts that most closely cor-
responded to their habitually consumed breakfast, followed
immediately by the day’s treatment (08.45 hours). Given
that the cognitive performance of children has previously
been shown to deteriorate throughout the morning(26,27), and
that this deterioration may serve to increase sensitivity to
any intervention, two post-dose assessments were carried out
using the Internet testing battery. These commenced at 1 h
(09.45 hours) and 3 h (11.45 hours) post-treatment respect-
ively. On day 85, the testing schedule was the same, with
the exception that participants also completed the Chalder
Fatigue Scale at the end of testing.
Interim assessments, comprising completion of the Internet
testing battery, were also undertaken via the Internet in the
participant’s own home, under parental supervision, 3 h post-
dose (participants were instructed to take their day’s treatment
at 08.45 hours with their breakfast) on days 29 and 57 via
access to an individual web-address. Participants and their
parents were e-mailed the day before Internet testing to
prompt completion at the appropriate time.
The running order of the active testing sessions of the pre-
sent study throughout the 85 d is shown in Fig. 1.
Following each of the laboratory assessments, participants
also undertook a separate, secondary, methodological assess-
ment comprising a number of measures designed for adults.
These data are not reported for brevity. In all instances, the
secondary data were always collected after the Internet
battery.
Statistics
The data from the experiment were subjected to three separate
analyses. The ‘acute’ analysis utilised the day 1 post-dose data
collected in the laboratory. The ‘interim’ analysis utilised the
day 29 and day 57 data collected over the Internet from the
participants’ own homes at 3 h post-dose. The ‘chronic’ anal-
ysis utilised the pre- and post-dose data collected on day 85 in
the laboratory.
All of the separate analyses (with the exception of the
Chalder Fatigue Scale data) were by repeated measures anal-
ysis of covariance (ANCOVA), with assessment as a repeated
measures term, and condition as an independent measures
term. To allow for any baseline differences that could
impact upon results, baseline data collected pre-dose on day
1 were included as a covariate. Where significant condition £
assessment interactions were found, these were explored with
planned comparisons of data from the placebo and vitamin/
mineral condition being carried out for each relevant assess-
ment utilising t tests with the mean squares error from
the ANCOVA as an error term and corrected means(28).
To ensure the overall protection level, all testing was two-
tailed; comparisons were strictly planned prior to the study
and only probabilities associated with these pre-planned
comparisons were calculated.
In the case of the Chalder Fatigue Scale, a one-way inde-
pendent measures ANCOVA of data from the laboratory
visit on day 85 was carried out, utilising data from the practice
day as a covariate.
Results
Acute (day 1) data analysis
There was a significant interaction between condition
and assessment on Arrow Flankers reaction time (F(1,
72) ¼ 4·15, P¼0·045) and accuracy (F(1, 72) ¼ 4·10,
P¼0·047). Planned comparisons at each time point revealed
a significant decrease in speed of performing the Arrow Flan-
kers task at 3 h (t(72) ¼ 2·38, P¼0·02) following vitamins/
minerals. At the same time point there was an improvement
in accuracy (% errors) on this measure following the active
treatment (t(72) ¼ 4·04, P¼0·0001). There was also a signifi-
cant condition £ assessment interaction on accuracy of
performing the Paired Associates task (F(1, 71) ¼ 5·92,
P¼0·017). Planned comparisons revealed that accuracy
Fig. 1. The 12-week testing regimen showing laboratory and ‘home’ testing sessions.
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on the Paired Associates task (number of errors) was signi-
ficantly improved following vitamins/minerals at 3 h post-
dose (t(71) ¼ 3·43, P¼0·001). These results are represented
in Fig. 2.
Interim (days 29, 57) data analysis
There was a main effect of treatment on the accuracy
(% errors) of performing both the Arrows task (F(1, 64) ¼ 7·22,
P¼0·009) and the Arrow Flankers task (F(1, 65) ¼ 6·30,
P¼0·015), with improvements evident following vitamin/
mineral administration.
There was a significant interaction between condition and
assessment on ‘jittery’ ratings (F(1, 65) ¼ 5·66, P¼0·02).
Planned comparisons on each day revealed that these ratings
were increased on day 29 (t(65) ¼ 3·21, P,0·002) following
vitamins/minerals. These results are represented in Fig. 3.
Chronic (day 85) data analysis
Accuracy on the Arrow Flankers task was significantly
improved following vitamins/minerals (F(1, 75) ¼ 4·45,
P¼0·038). Conversely, a significant decrement was seen fol-
lowing vitamins/minerals in terms of the accuracy of perform-
ing the Picture Recognition task (F(1, 72) ¼ 6·79, P¼0·011).
There was a significant interaction between condition and
assessment on ‘jittery’ ratings (F(2, 150) ¼ 4·55, P¼0·012).
Planned comparisons at each time point revealed that ‘jittery’
ratings for the vitamins/minerals group were reduced also pre-
dose (t(150) ¼ 4·52, P,0·001). These results are represented
in Fig. 4.
Unadjusted mean data for the acute, interim and chronic
analyses of the cognitive and mood data are shown in
Tables 3 and 4 respectively.
Chalder fatigue scale (day 85)
There were no significant differences on the Chalder Fatigue
Scale.
Discussion
The most striking finding from the current study was a consis-
tent pattern of enhancement across the attention task com-
ponents of the battery, which was apparent throughout the
assessments. The vitamin/minerals treatment improved accu-
racy of performance of the Arrows task during the day 29
and day 57 home assessments. A similar pattern was evinced
in terms of accuracy on the Arrow Flankers task, although this
effect was apparent 3 h after the first dose of vitamins/minerals
(day 1) and was similarly sustained throughout both home
testing sessions (days 29 and 57) and the day 85 laboratory
assessment. It should, however, be noted that the effect on
accuracy of the Arrow Flankers task on day 1 was coupled
with slower reaction times on that task at the same time
point (but not subsequently).
In contrast with these improvements in performance, micro-
nutrient supplementation was associated with decrements in
Picture Recognition (% errors) on day 85.
The two tasks that were consistently improved by sup-
plementation rely, predominantly, on attentional resources.
In this respect, the Arrows task is a straightforward ‘choice
reaction time’ task assessing focused attention and the slightly
more complex Arrow Flankers task has been described as
assessing attention in the presence of distracting information.
This would seem to argue for the administration of multi-
vitamins/minerals having a specific beneficial impact on
selective attention. Importantly, no task with a memory com-
ponent was consistently enhanced by the treatment, again
supporting a selective effect on attentional processing.
Fig. 2. Adjusted data for measures that generated a significant treatment £ assessment interaction on the analysis of covariance performed on the acute data
from 1 and 3 h post-dose on day 1 (*P,0·05; ***P,0·001; from planned comparisons between treatments at each time point). RT, Reaction time. A, placebo; B,
vitamins.
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Interestingly, previous studies assessing the impact of vita-
min/mineral supplementation in children have focused almost
exclusively on the measurement of intelligence (intelligence
quotient) rather than cognitive functioning per se. Whilst
the findings from these studies are not entirely unequivocal
(for reviews, see Haller(1) and Benton(14)), where significant
differences have been found they have been positive and
evinced on non-verbal, as opposed to verbal, aspects of intel-
ligence. Benton(14) notes that verbal intelligence is a product
of environment and experience and is a measure of specific
Fig. 3. Adjusted data for measures that generated a significant main effect (a,b) or treatment £ assessment interaction effect (c) on the analysis of covariance
(ANCOVA) performed on the home Internet data from 3 h post-dose on days 29 and 57 (*P,0·05; **P,0·01; ***P,0·005 – (a,b) from the ANCOVA – (c) from
the planned comparisons between treatments at each assessment). A, Placebo; B, vitamins.
Fig. 4. Adjusted data for measures that generated a significant main effect (a,b) or treatment £ assessment interaction effect (c) on the analysis of covariance
(ANCOVA) performed on the chronic data from pre-dose, 1 h and 3 h on day 85 (*P,0·05; ***P,0·005 – (a,b) from the ANCOVA – (c) from the planned compari-
sons between treatments at each assessment). A, Placebo; B, vitamins.
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Table 3. Unadjusted cognitive task data from day 1 (acute analysis – n 75), days 29 and 57 (interim analysis – n 68) and day 85 (chronic analysis – n 78)‡
(Mean values and standard deviations)
Acute assessment (day 1) Interim assessment (days 29 and 57) Chronic assessment (day 85)
Measure
Baseline 1 h Post 3 h Post Day 29 Day 57 Pre-dose 1 h Post 3 h Post
n 75 Mean SD Mean SD Mean SD n 68 Mean SD Mean SD n 78 Mean SD Mean SD Mean SD
Arrows RT (ms) Placebo 72 504 73 501 80 514 108 67 484 91 497 92 77 497 93 498 92 499 89
Vitamins 504 64 516 118 522 114 506 92 505 81 501 76 505 84 520 101
Arrows (% error) Placebo 4·3 3·9 8·0 6·0 8·6 6·1 4·9† 4·8 7·3† 6·7 4·9 5·2 10·9 9·5 11·7 10·7
Vitamins 5·1 3·7 8·4 5·2 9·5 8·5 4·9† 3·7 4·7† 4·4 3·6 3·4 9·4 5·7 10·9 7·8
Arrow Flankers RT (ms) Placebo 646 122 640 132 614 122 612 123 616 113 616 107 618 113 592 92
Vitamins 644 85 623 88 635* 98 617 95 613 80 636 101 633 90 609 86
Arrow Flankers (% error) Placebo 3·6 3·8 5·7 5·8 7·6 6·5 5·5† 4·4 7·8† 10·4 5·0† 5·4 8·4† 7·4 8·7† 9·3
Vitamins 5·0 4·0 6·4 5·9 5·5* 4·4 5·2† 3·6 4·4† 3·5 5·7† 5·3 6·3† 6·6 7·5† 7·6
Paired Associates RT (ms) Placebo 74 804 173 812 153 806 168 67 779 157 764 161 767 152 764 175 764 154
Vitamins 782 141 768 123 779 163 751 162 772 120 784 140 802 173 794 176
Paired Associates (% error) Placebo 2·8 3·2 4·8 4·8 5·6 5·8 2·7 3·1 2·3 2·1 2·6 3·0 4·3 4·0 3·9 3·4
Vitamins 2·3 3·3 5·3 4·3 2·8* 2·1 2·9 3·9 3·1 2·6 2·4 2·3 3·9 2·8 4·3 4·9
Sentence Verification RT (ms) Placebo 72 2079 699 2007 732 1903 723 67 2063 1190 1986 1057 77 2022 1012 1959 1191 1760 769
Vitamins 2375 887 2227 898 2129 786 2150 801 2197 993 2183 903 2031 886 2077 1050
Sentence Verification (% error) Placebo 9·0 6·9 9·4 6·4 11·9 7·9 9·6 7·1 9·0 7·8 9·3 6·7 10·6 9·9 12·9 12·4
Vitamins 12·2 10·5 13·2 10·2 13·7 9·9 10·2 8·6 11·3 9·1 11·3 8·5 13·6 9·8 13·3 11·0
Picture Recognition RT (ms) Placebo 988 220 929 205 970 422 59 919 510 801 212 75 871 188 852 151 856 189
Vitamins 960 281 904 204 953 287 864 328 962 365 1003 323 867 242 885 370
Picture Recognition (% error) Placebo 7·1 0·9 12·4 1·4 14·7 1·3 11·8 2·1 8·8 1·4 4·5† 0·6 13·4† 1·2 14·2† 1·1
Vitamins 5·4 1·0 13·5 1·6 15·9 1·6 14·6 2·2 9·7 1·7 6·1† 1·0 14·3† 1·4 16·5† 1·5
Word Recognition RT (ms) Placebo 74 882 181 794 199 787 233 814 258 775 195 77 835 205 786 241 767 242
Vitamins 887 178 864 220 836 207 845 212 864 269 860 194 814 212 812 301
Word Recognition (% error) Placebo 16·4 1·4 21·6 1·6 20·3 1·4 17·2 1·3 17·1 1·5 16·2 1·1 20·0 1·1 22·0 1·3
Vitamins 16·4 1·3 19·8 1·3 21·1 1·5 15·6 1·5 14·3 1·7 15·6 1·4 20·7 1·3 22·3 1·2
RT, reaction time.
* Significant planned comparison (P , 0·05) between treatments on measure that generated a treatment £ assessment interaction.
† Significant main effect of treatment across assessments (P , 0·05; analysis of covariance).
‡ Where a specific task resulted in a reduced dataset the number of participants contributing data to the specific analysis is shown within the Table. For details of subjects and procedures, see Materials and methods.
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Table 4. Unadjusted mood visual analogue scale data from day 1 (acute analysis – n 75), days 29 and 57 (interim analysis – n 68) and day 85 (chronic analysis – n 78)†
(Mean values and standard deviations)
Acute assessment (day 1) (n 75)
Interim assessment (day 29 and 57)
(n 68) Chronic assessment (day 85) (n 78)
Baseline 1 h Post 3 h Post Day 29 Day 57 Pre-dose 1 h Post 3 h Post
Measure Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Relaxed Placebo 54·23 21·00 63·1 17·4 62·0 23·5 62·1 21·0 60·2 18·3 56·2 19·3 60·8 21·0 67·2 21·3
Vitamins 61·64 19·52 63·5 23·6 64·1 20·6 64·0 22·3 61·9 26·6 59·9 23·5 62·0 25·9 60·1 27·9
Alert Placebo 40·38 22·03 54·6 23·0 57·0 22·6 54·2 25·1 61·7 19·7 52·7 20·6 55·0 23·2 57·5 22·8
Vitamins 50·53 20·85 56·8 25·3 60·1 21·0 64·7 20·8 65·2 24·9 50·6 27·3 59·7 25·7 58·6 24·3
Jittery Placebo 27·82 20·18 27·0 20·7 29·9 20·4 19·0 18·1 33·3 22·7 30·4 23·9 30·7 25·6 26·3 21·6
Vitamins 26·11 19·27 32·0 25·4 28·9 22·3 26·6* 22·1 28·5 26·4 18·9* 17·9 26·5 21·9 28·3 24·8
Tired Placebo 63·03 24·79 44·3 27·1 42·2 27·0 45·9 25·7 38·9 20·6 60·3 22·6 48·5 23·0 44·1 24·9
Vitamins 52·56 26·45 33·0 26·0 34·5 24·1 34·0 26·6 32·3 24·3 50·1 30·5 36·0 26·9 36·0 27·8
Tense Placebo 30·31 16·98 30·9 22·3 27·5 21·7 26·3 21·4 29·1 21·9 35·3 26·0 30·3 24·2 28·4 23·1
Vitamins 31·31 22·57 28·5 17·7 28·3 18·1 22·3 19·2 25·7 24·3 24·7 22·5 26·4 21·8 30·3 23·1
Headache Placebo 17·44 24·08 16·4 21·8 17·1 24·0 18·0 26·6 16·3 24·3 20·6 28·0 18·1 21·9 23·4 25·7
Vitamins 16·11 20·79 12·3 16·2 15·0 20·0 18·5 23·6 19·1 25·7 19·9 25·6 17·6 21·8 20·9 23·5
Overall mood Placebo 68·33 15·97 77·1 14·9 71·8 21·9 76·1 18·7 75·5 18·3 72·6 17·6 74·3 15·2 76·5 19·9
Vitamins 69·47 19·06 77·8 17·5 74·8 18·8 70·8 25·4 73·7 18·4 69·4 22·9 71·8 21·4 73·9 20·1
Mentally fatigued Placebo 40·31 20·12 40·4 21·0 41·5 26·6 33·6 24·3 31·2 22·1 37·8 24·2 30·7 18·7 34·3 23·4
Vitamins 37·25 19·73 39·9 24·0 36·1 26·0 30·3 23·0 32·7 28·9 32·4 24·3 31·9 28·0 31·8 25·2
Happy/sad Placebo 19·92 15·21 19·0 18·2 18·2 18·9 17·3 16·2 19·9 17·1 19·0 17·4 17·4 18·7 17·7 17·4
Vitamins 20·58 17·03 20·0 16·7 19·7 16·6 25·9 21·3 22·2 21·0 18·0 16·5 15·1 16·4 17·7 18·4
Stressed/calm Placebo 73·33 18·70 71·0 21·9 73·1 24·7 71·1 21·3 70·5 20·6 72·2 22·0 75·0 17·5 74·1 19·1
Vitamins 64·36 23·29 65·2 25·6 64·2 23·7 66·8 22·5 63·9 25·7 68·5 25·6 72·6 26·4 72·9 27·2
* Significant planned comparison (P , 0·05) between treatments on measure that generated a treatment £ assessment interaction.
† For details of subjects and procedures, see Methods and materials.
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information and vocabulary, whereas non-verbal intelligence
reflects basic problem solving and reasoning power. Any sup-
plementation that had an effect on brain biochemistry would
therefore be expected to impact non-verbal intelligence as
this domain reflects simple ‘biological potential’(14). Whilst
the results here are broadly in line with this differentiation,
it is also notable that any improvement in measures of ‘non-
verbal intelligence’ previously seen following vitamins/min-
erals could also be more parsimoniously explained by a
simple improvement in general attention, as possibly indicated
by the present results.
The most surprising facet of the improvement in attention
task performance seen here is that it became evident by 3 h
post-dose on the first day of treatment. Although it is possible
that this effect merely reflects a speed–accuracy trade-off,
given that reaction time was significantly slower at the same
time point, this effect was also accompanied by a single sig-
nificant improvement in the accuracy of the Paired Associate
task at the same time point. To the best of our knowledge,
the possibility that vitamins or minerals could exert beha-
vioural effects after a single dose has not been explored.
Nonetheless, there is emerging evidence that micronutrient
supplementation may have acute effects upon cognition-rel-
evant physiological processes within the same time-frame as
the effects observed here. For example, various chronic and
acute disruptions to endothelial function can be reversed by
acute administration of micronutrients. Thus, 5mg folic acid
improved flow-mediated dilatation at 2 and 4 h post-adminis-
tration in coronary artery disease patients – an effect that
was maintained following 6 weeks supplementation(29). The
same parameter is reduced during and in the hours and days
following underwater diving. This measure was selectively
improved after diving in healthy professional divers who
had been administered 2 g vitamin C with 400 IU vitamin E
2 h prior to the dive (of unspecified duration)(30). Nutritional
loads can also negatively impact upon endothelial function.
Co-administration of 800 IU vitamin E prevented the
disruption to endothelial function (here assessed by brachial
artery post-occlusion peak flow) associated with fat ingestion
measured 3 h post-administration(31). Similarly 2 and 3 h
preloading with a combination of 2 g vitamin C and 800 IU
vitamin E attenuated the reduction in endothelial function
associated with a 75 g glucose load(32). We have previously
argued that interventions that improve the central delivery of
metabolic substrates are likely to act as cognition enhan-
cers(20,21). However, these studies used doses approximately
two orders of magnitude higher than those in the current
trial and had very different (non-cognitive) outcomes in
different populations. Given the paucity of data regarding
acute effects of micronutrient administration, it would be
unwise to attribute any of the effects observed here to endo-
thelial or other effects. Nevertheless, such findings
argue strongly for further studies into acute effects of micro-
nutrient supplementation.
Although the mechanisms underlying these putative effects
are unknown and a detailed discussion of potential processes
involved is beyond the scope of this empirical paper, the
reader is directed to a recent review(2) for a detailed consider-
ation of mechanisms relevant to brain health and cognitive
function. In this review, the authors describe direct and indir-
ect modulation by micronutrient supplementation of major
neurotransmitter and neuromodulator systems. These include
(but are not restricted to) influences via amino acid modu-
lation on GABAergic, serotonergic, dopaminergic, adrenergic
and histaminergic pathways.
Whilst the pattern of results across the attention tasks is
remarkably consistent, with effects evinced across the acute,
interim ‘at home’ and chronic assessments, the decrements
seen on the Picture Recognition task (% errors) were evinced
solely during the chronic (day 85) laboratory session. The fac-
tors underlying this decline in performance are difficult to
delineate. In general, this and the Word Recognition task
were poorly performed, with many participants barely exceed-
ing chance performance on the later assessments on day 85.
The task was also positioned late in the battery. The significant
difference may therefore represent an interaction between the
treatment and task demands and/or waning attention. This
interpretation would also raise the question as to whether
the attention task improvements were domain specific, or
simply the result of these tasks being first in the battery. Alter-
natively, in the absence of any other significant decrements
during either the acute or interim assessments on the Picture
Recognition task, or indeed the other memory tasks within
the battery, it is possible that this finding simply represents
a chance fluctuation in performance (type I error).
Similarly, the interactions on the ‘jittery’ mood scale (with
an increase on day 29, but a decrease pre-dose on day 85) are
also difficult to interpret. However, it may be relevant that this
scale was included simply on the basis that it was contained
within the set of visual analogue scales utilised here(24,25)
and was generally not well understood by the children.
Indeed ‘jittery’ had to be explained to the vast majority of
the cohort by the researchers. This suggests that, again,
these interactions may simply represent type I errors as a con-
sequence of fairly random variations due to a lack of under-
standing of the question.
Similarly, it should be noted that any statistical technique
that uses a measure of pre-treatment baseline performance as
a yardstick against which to measure any subsequent treat-
ment-related effect (as the ANCOVA did in this case) runs
the risk of a between groups difference in baseline, covariate
performance contributing to, or negating, the effects of the
treatment by a subsequent regression to the mean. In this
case, there were numerical, but non-significant, differences
in the scores for placebo on the measures of attention that sub-
sequently evinced the pattern of significant enhancement post-
dose. These pre-dose differences could suggest two further
interpretations rather than the straightforward ‘net benefits’
proposal made earlier. The first is that the numerical, but
non-significant, pre-dose differences represent a chance fluctu-
ation in performance that led to, or contributed to, the signifi-
cant post-dose differences in scores. However, this proposition
would suggest that all of the post-dose scores, including
both post-dose assessments on day 1, should be similarly
and equally modulated (as they all have the same pre-dose
covariate score). This was patently not the case, with the
Arrows Flankers task evincing a treatment £ assessment inter-
action (i.e. no difference at 1 h post-dose, but an improvement
at 3 h) on day 1, and the somewhat less demanding Arrows
task only showing improvements that became apparent after
29 d. The second alternative interpretation would be that the
treatment had attenuated a genuine decrement in performance
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in the ‘vitamin group’. However, it should be stressed that
there was no evidence of a significant pre-dose difference in
the groups. The multiple potential interpretations of the results
seen here do, however, support the assertion that the effects of
supplementation of this nature require further investigation.
The use of a cohort of healthy children, who were not
selected on the basis of an examination of their dietary
habits, was either a strength, or alternatively weakness of
the study, depending on one’s view point. Whilst the lack
of fine-grained dietary information precludes an assessment
of the comparative effects of vitamins/minerals in children
with different nutritional backgrounds, the use of a simple
cross-section does seem to suggest that the results can be gen-
eralised to relatively normal populations. That having been
said, there is also nothing to suggest that the children under
investigation did not include the high proportions reported to
be deficient in one or more micronutrients(16–19). It should
be noted that an analysis of BMI for the participants in the
current study revealed that 26% were overweight (as classi-
fied in Cole et al.(33)). However, this level is in line with
figures reported by the International Obesity Task Force in
2004 for UK children.
The combination of vitamins, minerals and amino acids pre-
sent in the active treatment in the present study does not allow
the results presented to be attributed to any one component.
However, the product tested is available internationally and
is aimed at improving physical development and neural per-
formance. This claim clearly requires validation and the pri-
mary aim of the current study was to ascertain whether
claims made by the manufacturers with regard to potentially
improved mental performance following administration have
any basis in fact. Further work in this area could examine
the constituent parts of this treatment in more detail, perhaps
focusing on attentional measures and including acute, as
well as chronic, assessment.
In conclusion, the results of the current study demonstrated
a consistent improvement in the accuracy of attention task
performance, in comparison with placebo, during 12 weeks’
supplementation with vitamins/minerals in healthy 8- to 14-
year-old children. Furthermore, the first signs of any effect
were detected 3 h following the first dose of vitamins on day
1 of the study. This represents the first observation of acute
behavioural effects of vitamins/minerals in human subjects.
Naturally, these observations require replication in larger
cohorts, but they do suggest that this matter should be given
some priority.
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